Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 26 2021 - 7:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of November 2021
001-36203
(Commission
File Number)
CAN-FITE
BIOPHARMA LTD.
(Exact
name of Registrant as specified in its charter)
10
Bareket Street
Kiryat
Matalon, P.O. Box 7537
Petach-Tikva
4951778, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
This
Report on Form 6-K (including the text under the heading “Financial Results”, the accompanying interim condensed consolidated
financial statements and “Forward Looking Statements” in the press release in Exhibit 99.1) is hereby incorporated by reference
into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-236064,
333-237443 and 333-249063), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents
or reports subsequently filed or furnished.
On
November 26, 2021, Can-Fite BioPharma Ltd. issued a press release announcing that it reported financial results for the nine months ended
September 30, 2021 and provided clinical and corporate updates. A copy of this press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date:
November 26, 2021
|
By:
|
/s/
Pnina Fishman
|
|
|
Pnina
Fishman
|
|
|
Chief
Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024